ListarGI- GRINCAR - Artigos por tema "Inotrope"

Mostrando ítems 1-3 de 3

    • Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use 

      Papp, Zoltán; Álvarez, Julián; Bettex, Dominique; Bouchez, Stefan; Brito, Dulce; Černý, Vladimir; Comin-Colet; Comin-Colet, Josep; Crespo-Leiro, María Generosa; Delgado-Jiménez, Juan F.; Édes, István; Eremenko, Alexander; Farmakis, Dimitrios; Fedele, Francesco; Fonseca, Candida; Fruhwald, Sonja; Girardis, Massimo; Guarracino, Fabio; Harjola, Veli-Pekka; Heringlake, Matthias; Herpain, Antoine; Heunks, Leo; Husebye, Tryggve; Ivancan, Višnja; Karason, Kristjan; Kaul, Sundeep; Kivikko, Matti; Kubica, Janek; Masip, Josep; Matskeplishvili, Simon; Mebazaa, Alexandre; Nieminen, Markku S.; Oliva, Fabrizio; Papp, Julius G.; Parissis, John; Parkhomenko, Alexander; Põder, Pentti; Pölzl, Gerhard; Reinecke, Alexander; Ricksten, Sven-Erik; Riha, Hynek; Rudiger, Alain; Sarapohja, Toni; Schwinger, Robert H. G.; Toller, Wolfgang; Tritapepe, Luigi; Tschöpe, Carsten; Wikström, Gerhard; Lewinski, Dirk von; Vrtovec, Bojan; Pollesello, Piero; Agostoni, Piergiuseppe (Wolters Kluwer, 2020-07)
      [Abstract] Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart ...

    • Long‐term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long‐Term Registry 

      Mebazaa, Alexandre; Motiejunaite, Justina; Gayat, Etienne; Crespo-Leiro, María Generosa; Lund, Lars H.; Maggioni, Aldo P.; Chioncel, Ovidiu; Akiyama, Eiichi; Harjola, Veli-Pekka; Seferovic, Petar M.; Laroche, Cécile; Sanz Julve, Marisa; Roig, Eulàlia; Ruschitzka, Frank; Filippatos, Gerasimos (Wiley, 2017-10-08)
      [Abstract] Aims. The aim of this study was to assess long‐term safety of intravenous cardiovascular agents—vasodilators, inotropes and/or vasopressors—in acute heart failure (AHF). Methods and results. The European Society ...

    • Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: GALACTIC‐HF Baseline Characteristics and Comparison With Contemporary Clinical Trials 

      Teerlink, John R.; Díaz, Rafael; Felker, G. Michael; McMurray, John J.V.; Metra, Marco; Solomon, Scott D.; Adams, Kirkwood F.; Anand, Inder; Arias‐Mendoza, Alexandra; Biering‐Sørensen, Tor; Böhm, Michael; Bonderman, Diana; Cleland, John G.F.; Corbalán, Ramón; Crespo-Leiro, María Generosa; Dahlström, Ulf; Echeverría Correa, Luis E.; Fang, James C.; Filippatos, Gerasimos; Fonseca, Cándida; Goncalvesova, Eva; Goudev, Assen R.; Howlett, Jonathan G.; Lanfear, David E.; Lund, Mayanna; Macdonald, Peter; Mareev, Vyacheslav; Momomura, Shin‐ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J.A.; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A.; Yilmaz, Mehmet B.; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Abbasi, Siddique A.; Varin, Claire; Malik, Fady I.; Kurtz, Christopher E. (Willey Online Library, 2020-09-20)
      [Abstract] Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach ...